Category Archives: Stem Cell Therapy

DUBLIN, Dec. 31, 2020 /PRNewswire/ -- The "Cell Therapy Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Cell Therapy Global Market Report 2020-30: COVID 19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global cell therapy market.

Major players in the cell therapy market are Fibrocell Science Inc., JCR Pharmaceuticals Co. Ltd., PHARMICELL Co. Ltd., Osiris Therapeutics Inc., MEDIPOST, Vericel Corporation, Anterogen Co. Ltd., Kolon TissueGene Inc., Stemedica Cell Technologies Inc. and AlloCure.

The global cell therapy market is expected to decline from $7.31 billion in 2019 to $7.2 billion in 2020 at a compound annual growth rate (CAGR) of -1.54%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $10.0 billion in 2023 at a CAGR of 11.55%.

The cell therapy market consists of sales of cell therapy and related services. Cell therapy (CT) helps repair or replace damaged tissues and cells. A variety of cells are used for the treatment of diseases includes skeletal muscle stem cells, hematopoietic (blood-forming) stem cells (HSC), lymphocytes, mesenchymal stem cells, pancreatic islet cells, and dendritic cells.

North America was the largest region in the cell therapy market in 2019. Asia Pacific is expected to be the fastest-growing region in the forecast period.

The cell therapy market covered in this report is segmented by technique into stem cell therapy; cell vaccine; adoptive cell transfer (ACT); fibroblast cell therapy; chondrocyte cell therapy. It is also segmented by therapy type into allogeneic therapies; autologous therapies, by application into oncology; cardiovascular disease (CVD); orthopedic; wound healing; others.

In August 2019, Bayer AG, a Germany-based pharmaceutical and life sciences company, acquired BlueRock Therapeutics, an engineered cell therapy company, for $1 billion. Through this transaction, Bayer AG will acquire complete BlueRock Therapeutics' CELL+GENE platform, including a broad intellectual property portfolio and associated technology platform including proprietary iPSC technology, gene engineering, and cell differentiation capabilities. BlueRock Therapeutics is a US-based biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology, and immunology, using a proprietary induced pluripotent stem cell (iPSC) platform.

The high cost of cell therapy hindered the growth of the cell therapy market. Cell therapies have become a common choice of treatment in recent years as people are looking for the newest treatment options. Although there is a huge increase in demand for cell therapies, they are still very costly to try. Basic joint injections can cost about $1,000 and, based on the condition, more specialized procedures can cost up to $ 100,000. In 2020, the average cost of stem cell therapy can range from $4000 - $8,000 in the USA. Therefore, the high cost of cell therapy restraints the growth of the cell therapy market.

Key players in the market are strategically partnering and collaborating to expand the product portfolio and geographical presence of the company. For instance, in April 2018, Eli Lilly, an American pharmaceutical company entered into a collaboration agreement with Sigilon Therapeutics, a biopharmaceutical company that focused on the discovery and development of living therapeutics to develop cell therapies for type 1 diabetes treatment by using the Afibromer technology platform. Similarly, in September 2018, CRISPR Therapeutics, a biotechnological company that develops transformative medicine using a gene-editing platform for serious diseases, and ViaCyte, a California-based regenerative medicine company, collaborated on the discovery, development, and commercialization of allogeneic stem cell therapy for diabetes treatment.

The rising prevalence of chronic diseases contributed to the growth of the cell therapy market. According to the US Centers for Disease Control and Prevention (CDC), chronic disease is a condition that lasts for one year or more and requires medical attention or limits daily activities or both and includes heart disease, cancer, diabetes, and Parkinson's disease. Stem cells can benefit the patients suffering from spinal cord injuries, type 1 diabetes, Parkinson's disease (PD), heart disease, cancer, and osteoarthritis.

According to Cancer Research UK, in 2018, 17 million cancer cases were added to the existing list, and according to the International Diabetes Federation, in 2019, 463 million were living with diabetes. According to the Parkinson's Foundation, every year, 60,000 Americans are diagnosed with PD, and more than 10 million people are living with PD worldwide. The growing prevalence of chronic diseases increased the demand for cell therapies and contributed to the growth of the market.

Key Topics Covered:

1. Executive Summary

2. Cell Therapy Market Characteristics

3. Cell Therapy Market Size And Growth 3.1. Global Cell Therapy Historic Market, 2015 - 2019, $ Billion 3.1.1. Drivers Of The Market 3.1.2. Restraints On The Market 3.2. Global Cell Therapy Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion 3.2.1. Drivers Of The Market 3.2.2. Restraints On the Market

4. Cell Therapy Market Segmentation 4.1. Global Cell Therapy Market, Segmentation By Technique, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

4.2. Global Cell Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

4.3. Global Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

5. Cell Therapy Market Regional And Country Analysis 5.1. Global Cell Therapy Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion 5.2. Global Cell Therapy Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/rblnmb

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Go here to read the rest:
Global Cell Therapy Market Report 2020: Market to Recover in 2023 - PRNewswire

Global Rheumatoid Arthritis Stem Cell Therapy Market: Overview

Rheumatoid arthritis is an inflammatory disease of the bodys supportive tissues, usually affecting an individuals toes and fingers. Inflammation is triggered by an abnormal response to the bodys normally functioning tissues. This results in malformed joints and severe pain. Stem cells are novel cells that are generated in regenerative centers of the body. They can be transformed into any other cell type in the body with the right kind of stimulus.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6864

Stem cell therapy for rheumatoid arthritis works on the principle of such cellular replacement. Stem cells are injected into a patients body and are transformed on site into anti inflammatory cells that limit the spread of this disease. Stem cells work better than traditional inflammation suppressing medicines because they are more organic and act in a targeted manner. In light of the development of innovations in allopathic medicine and demand of people for better healthcare facilities, the market for rheumatoid arthritis stem cell therapy is expected to grow at a commendable pace from 2019 to 2029, opines TMRR.

Global Rheumatoid Arthritis Stem Cell Therapy Market: Competitive Landscape

Handful of pharmaceutical manufacturing facilities is seen to be involved in the production of stem cell therapy solutions.

Significant players n the market include.

Some of these manufacturers are established players in the pharmaceutical industry and have branched into the foray of stem cell therapy. Their established base for pharmaceutical therapy makes the distribution and marketing of stem cell therapy easier. Innovations in this market scenario are funded by these players to increase patient compliance with therapy.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=6864<ype=S

Global Rheumatoid Arthritis Stem Cell Therapy Market: Key Trends and Drivers

Global Rheumatoid Arthritis Stem Cell Therapy Market: Regional Analysis

North America and Europe currently lead in the rheumatoid arthritis stem cell therapy market. This might be because of the presence of a robust healthcare infrastructure that is under pressure from people for better facilities. Moreover, most innovatory laboratories are based in these regions and enjoy supple funding from regional governments. Population in these regions too is more aged than in other regions of the world. Hence, market growth for stem cell therapy should be good here.

The Asia Pacific region (APAC) is expected to register the fastest growth in this market in the coming years. A growing healthcare infrastructure that derives protocol from western medicine should support the growth of stem cell therapy. Population here is also expected to age in future decades, and an increasingly stressful lifestyle shall undoubtedly bring an increase in incidence of stressful conditions like rheumatoid arthritis.

Based on treatment type, the global rheumatoid arthritis stem cell therapy market can be segmented into:

Based on application, the global rheumatoid arthritis stem cell therapy market can be segmented into:

Based on distribution channel, the global rheumatoid arthritis stem cell therapy market can be segmented into:

Based on geography, the global rheumatoid arthritis stem cell therapy market can be segmented into:

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6864

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,3739 Balboa St # 1097,San Francisco, CA 94121United StatesTel: +1-415-520-1050

See the original post here:
Rheumatoid Arthritis Stem Cell Therapy Market Latest Trends and Future Growth Study by 2029 - Farming Sector

PHOENIX, Dec. 31, 2020 /PRNewswire/ --(OTC CELZ) Creative Medical Technology Holdings Inc. announced today positive preclinical data using ImmCelz in treatment of a model of heart attack.

Patent application #63/132472, entitled "Treatment of Heart Failure and/or Post Infarct Pathological Remodeling by Ex Vivo Reprogrammed Immune Cells" covers data in which mice with restricted blood flow to the heart had significantly improved survival when treated with ImmCelz as compared to control mice.

"The role of the immune system in numerous aspects of regenerative medicine can not be overstated." Said Dr. Amit Patel, Board Member of the Company and co-inventor of the patent. "The data described today, while preliminary, supports the belief that ImmCelz, which is a "regenerative immunotherapy" can be applied across a broad range of conditions."

The ImmCelz product, based on decades of immunological research by Drs Thomas Ichim and Amit Patel, involves extraction of patient immune cells, "training" the immune cells to exhibit regenerative properties by incubation with regenerative cells outside of the body, followed by re-infusion of the patient's own cells. To date the Company has demonstrated that ImmCelz has therapeutic activity in stroke and liver failure.

"It is my honor that the work we initiated more than a decade ago is coming to fruition." Said Thomas Ichim, Ph.D, coinventor of the patent. "Ten years ago, Dr. Patel, myself and a team of colleagues described the potent synergies that occur when various cell types are utilized in combination for treatment of heart failure1. ImmCelz is the product of all these years of working and perfecting multi-cellular approaches to regenerative medicine."

"As we round out 2020, we have significantly expanded our Intellectual Property portfolio based on many years of collaborative research and development. Utilizing the ImmCelz technology for the treatment of heart failure is an excellent addition to this robust patent portfolio as it effects millions of patients in the U.S. alone. Patients with end stage heart failure in many cases have no options but heart transplantation, which is extremely limited." Said Timothy Warbington, President and CEO of the Company. "We are excited with the progress that the Company is making in advancing ImmCelz, which approaches regenerative medicine from a completely unique perspective. Given that the active cells in ImmCelz are derived from the same patient, we anticipate an accelerated path to FDA Investigational New Drug (IND) clearance."

"We encourage industry colleagues and other interested parties to review our early priority date patent filings to learn more about the ImmCelz technology and how it applies to multiple indications" Mr. Warbington further said.

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of urology, neurology and orthopedics and trades on the OTC under the ticker symbol CELZ. For further information about the company, please visitwww.creativemedicaltechnology.com.

Forward Looking Statements

OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website atwww.sec.gov.

Creativemedicaltechnology.comwww.StemSpine.comwww.Caverstem.comwww.Femcelz.com

1 Ichim et al. Combination stem cell therapy for heart failure. Int Arch Med. 2010; 3: 5. Combination stem cell therapy for heart failure (nih.gov)

SOURCE Creative Medical Technology Holdings, Inc.

Home

Read more here:
Creative Medical Technology Holdings Announces Patent filing based on Preclinical Data in Model of Heart Attack using ImmCelz Regenerative...

PHOENIX, Dec. 29, 2020 /PRNewswire/ --(OTC-CELZ)Creative Medical Technology Holdings Inc. announced today novel data and patent filing No. 63131261 describing the ability of ImmCelz to reverse liver failure in the carbon tetrachloride preclinical model of hepatocyte necrosis.

These findings are the basis for a patent filing covering various means of generating the ImmCelz product in a hepatoprotective specific manner. The Company has previously reported that ImmCelz is capable of treating animal models of stroke,1 as well as inducing "immunological tolerance" in a model of autoimmune rheumatoid arthritis.2

The work is an extension of previously published findings of Dr. Thomas E. Ichim, in which mesenchymal stem cells were capable of inhibiting progression of liver failure.3

"I am proud of the work the team at Creative Medical Technologies is conducting in advancing the concept of immunologically-mediated regeneration,"said Dr. Ichim, Co-inventor of the patent. "ImmCelz is an advancement on our previous liver failure work due to the fact that we have shown transfer of regenerative activity from the stem cell to the immune cell. Immune cells possess ability to home to injured tissues faster than stem cells due to their smaller size. Additionally, immune cells possess immunological memory, which we believe may be applied to the concept of regeneration."

"While stem cell therapeutics are recognized as the future of medicine, I believe it is important to realize that many activities of stem cells are mediated by changes to the immune system," said Dr. Amit Patel, Board Member of the Company and Co-Inventor of the Patent Application. "ImmCelz represents a fundamental advancement in regenerative medicine in that instead of administering stem cells in the body to induce immune modulation, we actually optimize the immune modulation in the laboratory before injecting immune cells into the patient."

Being at the forefront in identifying novel regenerative treatment options, the Company possesses numerous issued patents in the area of cellular therapy, including patent no. 10,842,815 covering use of T regulatory cells for spinal disc regeneration, patent no. 9,598,673 covering stem cell therapy for disc regeneration, patent no. 10,792,310 covering regeneration of ovaries using endothelial progenitor cells and mesenchymal stem cells, patent no. 8,372,797 covering use of stem cells for erectile dysfunction, and patent no. 7,569,385 licensed from the University of California covering a novel stem cell type.

"Liver failure represents a significant unmet medical need and I am extremely excited that ImmCelz has the potential to help the numerous patients on the liver transplant waiting list who currently have no other option.

With growing validation and acceptance of such technologies, the company intends to continue to broaden its intellectual property portfolio by compiling research data and filing patents, in order to record early filing dates and increase the likelihood of our receiving patent issue.

We continue to welcome opportunities with collaborators and Key Opinion Leaders as we are dedicated to accelerating the further development of our technology."

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of urology, neurology and orthopedics and trades on the OTC under the ticker symbol CELZ. For further information about the company, please visitwww.creativemedicaltechnology.com.

Forward Looking Statements

OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website atwww.sec.gov.

Creativemedicaltechnology.comwww.StemSpine.comwww.Caverstem.comwww.Femcelz.com

1 Creative Medical Technology Holdings Identifies Mechanism of Action of ImmCelz Stroke Regenerative Activity (prnewswire.com)2 Creative Medical Technology Holdings Reports Positive Preclinical Data on ImmCelz Immunotherapy Product in Rheumatoid Arthritis Model | BioSpace 3 Human endometrial regenerative cells alleviate carbon tetrachloride-induced acute liver injury in mice | Journal of Translational Medicine | Full Text (biomedcentral.com)

SOURCE Creative Medical Technology Holdings, Inc.

Home

See the original post:
Creative Medical Technology Holdings Announces Reversion of Liver Failure Using ImmCelz Personalized Cellular Immunotherapy in Preclinical Model -...

New Jersey, United States,- The report, titled Stem Cell Therapy Market Research Report is based on the extensive analysis of analysts and contains detailed information on the global market area. A detailed examination of the business landscape, as well as the essential parameters that shape the marketing matrix of the market, is included.

A thorough qualitative and quantitative study of the global market has been conducted in this report. The study takes into account various important aspects of the market by focusing on historical and forecast data. The report provides information on the SWOT analysis as well as Porters Five Forces Model and the PESTEL analysis.

The Stem Cell Therapy Market research documentation provides details on drivers and restraints, regional growth opportunities, market size, as well as the spectrum of competition, prominent market candidates, and segment analysis.

The following Manufacturers are covered in this report:

The report aims to enumerate various data and updates related to the World Market while developing various growth opportunities that are believed to support the market growth at a significant rate during the forecast period. The report provides an insightful overview of the Stem Cell Therapy market along with a well-summarized market definition and detailed industry scenario.

A comprehensive summary revolves around market dynamics. The segment encompasses insights into the drivers driving the growth of the Stem Cell Therapy market, restrictive parameters, existing growth opportunities in the industry, and the numerous trends that define the global marketplace. The report also includes data on pricing models and a value chain analysis. The expected growth of the market during the analysis period based on the estimates and historical figures has also been factored into the study.

The Stem Cell Therapy market report provides details of the expected CAGR recorded by the industry during the investigation period. Additionally, the report includes a number of technological advances and innovations that will boost the industrys prospects over the estimated period.

The report further studies the segmentation of the market based on product types offered in the market and their end-use/applications.

1.High Content Screening Market, By End User:

2.High Content Screening Market, By Application:

3.High Content Screening Market, By Products:

4.High Content Screening Market, By Technology:

Geographic Segmentation

The report offers an exhaustive assessment of different region-wise and country-wise Stem Cell Therapy markets such as the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

North America, Europe, Asia-Pacific, Latin America, The Middle East and Africa

What are the main takeaways from this report?

A comprehensive price analysis was carried out in relation to product area, range of applications and regional landscape A comprehensive round up of the key market players and leading companies operating in the Stem Cell Therapy Market to understand the competitive perspective of the global marketplace Important information on the regulatory scenario that defines the market, as well as the inflow of investments from majority stakeholders in the world market An in-depth assessment of the various trends that are fueling overall market growth and their impact on global market projection and dynamics A descriptive guide that identifies the key aspects along with the many growth opportunities in the Stem Cell Therapy market A detailed documentation of a wide variety of ongoing issues in the world market that will encourage important developments

Some Points from Table of Content

1. Study coverage2. Summary3. Stem Cell Therapy Market Size by Manufacturer4. Production by region5. Consumption by region6.Stem Cell Therapy Market Size by Type7. Stem Cell Therapy Market size according to application8. Manufacturer profiles9. Production forecasts10. Consumption forecasts11. Analysis of customers upstream, industrial chain and downstream12. Opportunities and challenges, threats and influencing factors13. Main results14. Appendix

Verified Market Intelligence is a BI enabled database service with forecasted trends and accurate market insights on over 20,000+ tracked markets helping organizations globally with their market research needs. VMI provides a holistic overview and global competitive landscape with respect to Region, Country, Segment and Key players for emerging and niche markets.

About Us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

View post:
Stem Cell Therapy Market Size, Share, Growth Trends, Revenue, Top Companies, Regional Outlook, and Forecast, 2020-2027 - LionLowdown

Global Stem Cell Therapy Market 2020-2025 Introduction and Scope:

The report on the Stem Cell Therapy Market aims to provide report readers with a diverse understanding of the different marketing opportunities prevalent in regional hubs. A thorough evaluation and evaluation of these factors can influence the prospects for gradual growth of the Stem Cell Therapy Market. The market research report provides an in-depth study of the market based on key segments such as product type, application, key companies and key regions, end users, and more. Research reports help participants understand their competitive strengths. It provides global information on the market, providing individual, weakness and competitive analysis for each participant. The report also covers the growth aspects of the market along with the challenges. The research report on the global Stem Cell Therapy Market provides information on the best manufacturers currently operating in this industry and a good market by market region.

The competitive landscape of the global Stem Cell Therapy Market is meticulously measured to identify key players in the arena by category and encourage novice market participants to step into the rapid market competition.

Request for a sample copy of this research report @ https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=re

The research report provides an assessment of the growth and other characteristics of the global Stem Cell Therapy Market by key regions and countries. The main regions with good markets in this industry are North America, Latin America, Europe, Asia Pacific and Middle East Africa. It also includes several strategies for estimating and determining market growth. It is also estimated that the global Stem Cell Therapy Market will determine the growth of certain segments of the industry. Additionally, this research report provides an analysis of the key drivers or drivers responsible for the growth of the Stem Cell Therapy Market. Additionally, the report provides some key reasons that could hinder the growth of the market during the forecast period. Therefore, this study provides an estimate of the growth of the market based on various segmentations and calculations by historical and current data.

Complete Summary with TOC Available @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=re

The information reflected in the Stem Cell Therapy Market Report comes from a variety of sources of information supported by primary and secondary research practices. This information comes from a variety of websites, journals and corporate websites that have been optimally validated by competent research analysts to ensure maximum adoption by market participants.

DROT Analysis: Global Stem Cell Therapy Market1. Drivers: This report scouts various lucrative factors driving growth.2. Barrier Analysis: A close review of threat potential and effective challenge management to ensure continued growth in the global Stem Cell Therapy Market3. Opportunity Mapping: In this section of the report, readers can get a detailed reference to identify untapped market opportunities that could accelerate growth.The Stem Cell Therapy Market report is thoroughly structured to include the development of important milestones in the competitive spectrum, while enhancing competition while highlighting advanced market players with a thorough guide to core competencies and investment skills. The research elements presented in this advanced report have been prepared to ensure smooth decision making based on thorough and unbiased research practices.

Stem Cell Therapy Market SegmentationType Analysis of Stem Cell Therapy Market:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

Applications Analysis of Stem Cell Therapy Market:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

Major Topics Covered in this Report:1. Study Coverage2. Executive Summary3. Stem Cell Therapy Market Size by Manufacturers4. Production by Regions5. Consumption by Regions6. Stem Cell Therapy Market Size by Type7. Stem Cell Therapy Market Size by Application8. Manufacturers Profiles9. Production Forecasts10. Consumption Forecast11. Upstream, Industry Chain and Downstream Customers Analysis12. Opportunities and Challenges, Threat and Affecting Factors13. Key Findings14. Appendix

Make An Enquiry About This Report @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=re

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Read more here:
Stem Cell Therapy Market (COVID-19 Analysis) 2020-2025 Is Booming Worldwide with Comprehensive Study Explores Huge Revenue Scope in Future - Farming...

The newly added research report illustrating details on global Stem Cell Therapy market delivers key insights on specific market elements such as competition intensity, regional growth opportunities, vendor profiles and requisite understanding of most potential growth triggers and vendor activities that harbinger growth in global Stem Cell Therapy market. Crucial details on SWOT analysis, PESTEL analysis and Porters Five Forces analytical reviews have been professed with great detail in the report to encourage high investment returns by leading players in global Stem Cell Therapy market. The report carries out a deep analytical study to identify and understand the potential of core factors that stimulate high end growth. The report includes an illustrative overview and serves as an ideal reference point to encourage thoughtful market discretion pertaining to current, historical and future ready business decisions, trends and technologies that have growth steering vigor.

Get PDF Sample Report of Stem Cell Therapy (COVID-19 Version) Market 2020, Click Here @ https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=Pallavi

This report gives a complete comprehension of different viewpoints, for example, monetary, creation in the Stem Cell Therapy market. The report contains the current situation of the market by utilizing the effective and exact chronicled information in different market fragments, for example, type and Application Different contextual analyses from different industry specialists are remembered for the report to shape the organizations.

The Stem Cell Therapy market report gives complete data of the development drivers and restrictions that will characterize the business development in the impending years. In addition, it recognizes the open doors existing across the different areas to additional guide business development.

Segmentation OverviewThe global Stem Cell Therapy market has been examined with ample detailing to disclose vital market specific developments across segment categories. Segment classification of the market structure has been encouraged by our seasoned in-house research experts to allow readers comprehend the versatility of the market in terms of product and service variation. Additional details on regional expanse and geography-based vendor investments are also discussed extensively based on which global Stem Cell Therapy market is splintered into type, application and end-user.

Browse the complete report Along with TOC @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=Pallavi

Stem Cell Therapy Market SegmentationType Analysis of Stem Cell Therapy Market:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

Applications Analysis of Stem Cell Therapy Market:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

COVID-19 Impact on Stem Cell Therapy Market:The outbreak of COVID-19 has brought along a global recession, which has impacted several industries. Along with this impact COVID Pandemic has also generated few new business opportunities for Stem Cell Therapy Market. Overall competitive landscape and market dynamics of Stem Cell Therapy has been disrupted due to this pandemic. All these disruptions and impacts has been analysed quantifiably in this report, which is backed by market trends, events and revenue shift analysis. COVID impact analysis also covers strategic adjustments for Tier 1, 2 and 3 players of Stem Cell Therapy Market.

Table of Contents Includes Major Pointes as follows:1.Stem Cell Therapy Market Overview2.Global Stem Cell Therapy Market Competition by Manufacturers3.Global Stem Cell Therapy Capacity, Production, Revenue (Value) by Region (2014-2019)4.Global Stem Cell Therapy Supply (Production), Consumption, Export, Import by Region (2014-2019)5.Global Stem Cell Therapy Production, Revenue (Value), Price Trend by Type6.Global Stem Cell Therapy Market Analysis by Application7.Global Stem Cell Therapy Manufacturers Profiles/Analysis8.Stem Cell Therapy Manufacturing Cost Analysis9.Industrial Chain, Sourcing Strategy and Downstream Buyers10.Marketing Strategy Analysis, Distributors/Traders11.Market Effect Factors Analysis12.Global Stem Cell Therapy Market Forecast (2019-2026)13.Research Findings and Conclusion14.Appendix

If you have any questions on this report, please reach out to us @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=Pallavi

About Us :

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Read more from the original source:
Impacts of COVID 19 on Stem Cell Therapy Market 2020 Size, Demand, Opportunities & Forecast To 2026 - Factory Gate

Global Stem Cell Therapy Market 2020-2025 Introduction and Scope:

The Global Stem Cell Therapy Market is a competitive source of real-time data and information related to important facts and figures related to market analysis, competitive spectrum, regional scope and opportunity assessment, and understanding barriers that are important growth catalysts. The details of the COVID-19 impact and possible damage recovery plan have been discussed at length to guide important business decisions. The report is ready to refer to documents that share important details of the market from a historical perspective, so readers can measure concurrent developments to make accurate growth speculations and make predictive assessments. The report provides an exclusive overview of the competitive spectrum to identify key giants and ambitious players seeking to easily drive market penetration in the global Stem Cell Therapy Market ecosystem.

This report on the global Stem Cell Therapy Market provides an easily accessible roadmap to assess the league of factors and influencers such as untapped market opportunities and trends pioneering a growth timeline favorable for this market.

Request for a sample copy of this research report @ https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=re

This consciously designed market research protocol inspires our research experts and predictors to devote more effort to discovering thorough information so that critical research colleagues and knowledge collectors can optimally find multidimensional information for the best market predictions. Do it. This Advanced Strategy-Based Stem Cell Therapy Market Report presentation is based on market size and dynamics, dominant and popular trends, market shares, investment plans, pricing strategies, and drivers driving overall steady and long-term growth in the global Stem Cell Therapy Market.

The Stem Cell Therapy Market report contains details related to various supplier activities, trend analysis, DROT assessment, and potential business decisions to ensure a successful position despite ongoing competition. In addition, in the report, readers will receive important company profiles, product development, pricing, production and details related to the development of raw materials and equipment that make up important report content.

The Stem Cell Therapy Market report also entails specific details on the analysis of COVID-19, skillfully highlighting potential details of the pandemic impact across the current state, in addition to hovering over future developments. The COVID-19 outbreak has had a myriad of impacts on businesses and their normal growth process, and this research report is designed to adequately encourage an efficient and fast recovery process.

Complete Summary with TOC Available @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=re

Key questions answered in the report:What are the key developments influencing the global Stem Cell Therapy Market and its growth?What is the impact of global Stem Cell Therapy Market development on industry and market participants in the near and far future?What types of global Stem Cell Therapy Market are evolving?What are the evolving applications of the global Stem Cell Therapy Market?What are the key characteristics that will influence the global Stem Cell Therapy Market growth during the study period?Who are the major global players operating in the market?How are the major players using the existing global Stem Cell Therapy Market situation?

Stem Cell Therapy Market SegmentationType Analysis of Stem Cell Therapy Market:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

Applications Analysis of Stem Cell Therapy Market:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

Major Topics Covered in this Report:1. Study Coverage2. Executive Summary3. Stem Cell Therapy Market Size by Manufacturers4. Production by Regions5. Consumption by Regions6. Stem Cell Therapy Market Size by Type7. Stem Cell Therapy Market Size by Application8. Manufacturers Profiles9. Production Forecasts10. Consumption Forecast11. Upstream, Industry Chain and Downstream Customers Analysis12. Opportunities and Challenges, Threat and Affecting Factors13. Key Findings14. Appendix

Make An Enquiry About This Report @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=re

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Link:
Stem Cell Therapy Market Size 2020 | Opportunities, Regional Overview, Top Leaders, Revenue and Forecast to 2025 - LionLowdown

Stem cells are biological cells which have the ability to distinguish into specialized cells, which are capable of cell division through mitosis. Amniotic fluid stem cells are a collective mixture of stem cells obtained from amniotic tissues and fluid. Amniotic fluid is clear, slightly yellowish liquid which surrounds the fetus during pregnancy and is discarded as medical waste during caesarean section deliveries. Amniotic fluid is a source of valuable biological material which includes stem cells which can be potentially used in cell therapy and regenerative therapies. Amniotic fluid stem cells can be developed into a different type of tissues such as cartilage, skin, cardiac nerves, bone, and muscles. Amniotic fluid stem cells are able to find the damaged joint caused by rheumatoid arthritis and differentiate tissues which are damaged. Medical conditions where no drug is able to lessen the symptoms and begin the healing process are the major target for amniotic fluid stem cell therapy. Amniotic fluid stem cells therapy is a solution to those patients who do not want to undergo surgery. Amniotic fluid has a high concentration of stem cells, cytokines, proteins and other important components. Amniotic fluid stem cell therapy is safe and effective treatment which contain growth factor helps to stimulate tissue growth, naturally reduce inflammation. Amniotic fluid also contains hyaluronic acid which acts as a lubricant and promotes cartilage growth.

Get Free Sample Copy With Impact Analysis Of COVID-19 Of Market Report @https://www.persistencemarketresearch.com/samples/23101

With increasing technological advancement in the healthcare, amniotic fluid stem cell therapy has more advantage over the other therapy. Amniotic fluid stem cell therapy eliminates the chances of surgery and organs are regenerated, without causing any damage. These are some of the factors driving the growth of amniotic fluid stem cell therapy market over the forecast period. Increasing prevalence of chronic diseases which can be treated with the amniotic fluid stem cell therapy propel the market growth for amniotic fluid stem cell therapy, globally. Increasing funding by the government in research and development of stem cell therapy may drive the amniotic fluid stem cell therapy market growth. But, high procedure cost, difficulties in collecting the amniotic fluid and lack of reimbursement policies hinder the growth of amniotic fluid stem cell therapy market.

The global amniotic fluid stem cell therapy market is segmented on basis of treatment, application, end user and geography:

You Can Buy This PMR Healthcare Report From Here @https://www.persistencemarketresearch.com/checkout/23101

Rapid technological advancement in healthcare, and favorable results of the amniotic fluid stem cells therapy will increase the market for amniotic fluid stem cell therapy over the forecast period. Increasing public-private investment for stem cells in managing disease and improving healthcare infrastructure are expected to propel the growth of the amniotic fluid stem cell therapy market.

However, on the basis of geography, global Amniotic Fluid Stem Cell Therapy Market is segmented into six key regionsviz. North America, Latin America, Europe, Asia Pacific Excluding China, China and Middle East & Africa. North America captured the largest shares in global Amniotic Fluid Stem Cell Therapy Market and is projected to continue over the forecast period owing to technological advancement in the healthcare and growing awareness among the population towards the new research and development in the stem cell therapy. Europe is expected to account for the second largest revenue share in the amniotic fluid stem cell therapy market. The Asia Pacific is anticipated to have rapid growth in near future owing to increasing healthcare set up and improving healthcare expenditure. Latin America and the Middle East and Africa account for slow growth in the market of amniotic fluid stem cell therapy due to lack of medical facilities and technical knowledge.

Some of the key players operating in global amniotic fluid stem cell therapy market are Stem Shot, Provia Laboratories LLC, Thermo Fisher Scientific Inc. Mesoblast Ltd., Roslin Cells, Regeneus Ltd. etc. among others.

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Go here to see the original:
The Amniotic Fluid Stem Cell Therapy Market to stay put between 2018 and 2026 - The Monitor

Dec. 28, 2020 12:00 UTC

BURLINGAME, Calif.--(BUSINESS WIRE)-- Humanigen, Inc.. (NASDAQ: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today announced the United States Patent and Trademark Office has issued a patent to the Company for the use of lenzilumab in prevention or treatment of cytokine storm and neurotoxicity in patients undergoing chimeric antigen receptor T (CAR-T) cell therapy.

The patent covers the use of lenzilumab to prevent or treat cytokine release syndrome (CRS), neurotoxicity and otherwise inhibit or reduce incidence or severity of CAR-T-related toxicities in patients undergoing CAR-T cell therapy. Lenzilumab binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), which has been identified as a key initiator of the inflammatory cascade triggering CAR-T cell therapy-related toxicities, such as CRS and neurotoxicity, which have been associated with prolonged hospitalization and intensive care unit stay.1,2

We believe lenzilumab can potentially play an important role in enhancing CAR-T cell therapy, and we are committed to advancing the development of lenzilumab to address cytokine storm associated with CAR-T cell therapy and other areas, said Cameron Durrant, MD, MBA, Chief Executive Officer, Humanigen. This patent underscores Humanigens pioneering approach to neutralizing GM-CSF with lenzilumab and the value of our robust pipeline across the many disease areas where cytokine storm plays a critical role, including COVID-19 and acute graft-versus-host disease.

The patent, titled Methods of Treating Immunotherapy-Related Toxicity Using a GM-CSF Antagonist, was issued on December 22, 2020 as U.S. Patent No. 10,870,703.

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The companys immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit http://www.humanigen.com.

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding the use of lenzilumab to treat CAR-T cell therapy-related toxicity, and statements regarding our beliefs relating to any of the other technologies in our current pipeline. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory approvals and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.

1 Sterner RM, Sakemura R, Cox MJ, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019;133(7):697-709. doi:10.1182/blood-2018-10-8817222 Fitzgerald JC, Weiss SL, Maude SL, et al. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Crit Care Med. 2017;45(2):e124-e131. doi:10.1097/CCM.0000000000002053

View source version on businesswire.com: https://www.businesswire.com/news/home/20201228005075/en/

Read this article:
Humanigen Secures US Patent for Lenzilumab in Preventing Cytokine Storm and Neurotoxicity Related to CAR-T Cell Therapy - BioSpace